Posted by Michael Wonder on 20 Jul 2020
ICER posts draft scoping document for the assessment of anaemia in chronic kidney disease treatments
20 July 2020 - Document open to public comment until 7 August 2020
The Institute for Clinical and Economic Review (ICER) has posted a Draft Scoping Document outlining a planned review of the comparative clinical effectiveness and value of treatments for anaemia in chronic kidney disease.
ICER’s report will focus on roxadustat (FibroGen), which is currently undergoing FDA review; a decision is expected at the end of this year.
